Preclinical Evaluation Of F-18 Fluoroethyltriazolyl PEGstilbenes As Potential PET Imaging Agents For Alzheimers Disease
Funder
National Health and Medical Research Council
Funding Amount
$673,238.00
Summary
Alzheimer's disease (AD) is the most common form of dementia and is becoming am ever increasing burden to the health system due to the aging of our population. Amyloid plaques are considered the hallmark of AD and a technique for their detection in vivo would be a breakthrough, not only for the diagnosis of AD but also for the development of drugs against AD. Nuclear medicine can image tissue function non-invasively. This project aims to develop new imaging agents to improve diagnosis of AD.